Hims & Hers Health, Inc. (HIMS) 2025 Annual Report: Key Investor Insights

Highlights from the 2025 Annual Report

• Fiscal Year End: December 31, 2025.
• Exchange: New York Stock Exchange (Symbol: HIMS).
• Market Capitalization: Public float approximately \$10.1 billion as of June 30, 2025, with the last reported sale price of \$49.85 per share.
• Outstanding Shares: 219,561,143 shares of Class A common stock and 8,377,623 shares of Class V common stock as of February 20, 2026.
• Filer Status: Large Accelerated Filer; Well-Known Seasoned Issuer.
• Regulatory Compliance: Full compliance with SEC reporting requirements, including Sarbanes-Oxley Section 404(b) auditor attestation.
• No Shell Company Status: Hims & Hers is not a shell company.
• Financial Statement Integrity: No corrections or restatements of previous financial statements reported.

Key Information & Potential Price-Moving Details for Shareholders

1. Strong Market Position and Capitalization

Hims & Hers Health, Inc. maintained a robust market presence in 2025, with an approximate market value of \$10.1 billion in public float. This valuation is based on a strong stock price of \$49.85 per share at the end of Q2 2025, and a considerable volume of freely tradable shares. The company continues to be listed on the NYSE under the ticker “HIMS,” with no non-voting stock outstanding, which simplifies the capital structure and voting power for common shareholders.

2. Solid Corporate Governance and Compliance

• Hims & Hers qualifies as a large accelerated filer and a well-known seasoned issuer, reinforcing its reputation among institutional investors.
• The company has fulfilled all its SEC reporting obligations for the past 12 months, and attestation on internal controls over financial reporting by its independent auditor has been completed with no adverse findings.
• There were no restatements or corrections to previously issued financial statements, a strong signal of sound accounting practices and internal controls.
• Hims & Hers is not an emerging growth company, nor a smaller reporting company, indicating its maturity and scale.
• The company is not a shell company, confirming that it is an operating entity with substantive business activities.

3. Capital Structure and Shareholder Composition

• As of February 20, 2026, the company had 219.6 million shares of Class A common stock and 8.4 million shares of Class V common stock outstanding. The structure provides clarity and transparency for investors regarding voting and economic rights.
• No non-voting shares are outstanding; all equity is represented by voting stock, which is favorable for corporate governance and shareholder rights.

4. Regulatory and Legal Environment

• Hims & Hers operates in a highly regulated sector (offices and clinics of doctors of medicine), subject to federal and state healthcare, privacy, and consumer protection laws.
• The company cautions investors regarding the potential for regulatory risks, especially around advertising and promotional activities for prescription and over-the-counter drugs. Any non-compliance can lead to enforcement actions, including warning letters, injunctions, or criminal prosecution.
• There is explicit mention of forward-looking risks related to legal and regulatory changes, ongoing litigation, and government actions—these are flagged as material risks that could affect future financial performance.

5. Risk Factors and Forward-Looking Statements

• The company highlights multiple risk factors, including its ability to innovate, expand offerings, maintain relationships with providers, and comply with evolving regulations. Any negative developments here could materially impact the business and share value.
• Investors are urged to review the detailed risk factors listed in the Annual Report, as these could meaningfully affect future results and the company’s valuation.
• Hims & Hers disclaims any obligation to update forward-looking statements, emphasizing that actual results could differ materially from current expectations.

Sections of Potential Interest for Shareholders

• Risk Factors (Item 1A): Extensive discussion of business, legal, and regulatory risks.
• Cybersecurity (Item 1C): Focus on data security and privacy, critical in healthcare.
• Legal Proceedings (Item 3): Details of ongoing or potential litigation that might affect financial performance.
• Management’s Discussion and Analysis (Item 7): Provides insight into strategy, financial condition, and key operational metrics.
• Financial Statements (Item 8): Core financial data for investors and analysts.

Conclusion

Investor Takeaway: Hims & Hers Health, Inc. enters 2026 with a strong public float, a clean bill of health on regulatory compliance and financial reporting, and no major unresolved audit or accounting issues. However, its sector remains highly regulated and exposed to legal and compliance risks that could materially impact future results and share price. Ongoing innovation, risk management, and regulatory compliance remain key for sustained shareholder value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full 10-K filing and consult with their financial advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

View Hims & Hers Health, Inc. Historical chart here